Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Pharmaceutical Journal of Indonesia Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Altifani Penelitian dan Pengabdian kepada Masyarakat Indonesian Journal of Innovation Multidisipliner Research Indonesian Journal of Innovation Multidisipliner Research
JAYA, NUR
Unknown Affiliation
Religion Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Civil Engineering, Building, Construction & Architecture Computer Science & IT Decision Sciences, Operations Research & Management Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Nursing Public Health Social Sciences Other

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
Literatur Review Trastuzumab Induced Cardiotoxicity (TIC) In Patient With Breast Cancer : Pharmacology Aspect, Mechanism of Cardiotoxicity, Risk Factor and Treatment Strategies Jaya, Nur
Pharmaceutical Journal of Indonesia Vol 5, No 1 (2019)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Breast cancer (BCA) is the most common cancer in women. Since the last 2 decades, early diagnosis and specific molecular targeted neoadjuvant and adjuvant therapy had been reducing breast cancer mortalities. Unfortunately, the improvement of the survival rate is followed by the emergence of cardiotoxicity effect from cancer therapy that had seen in several cases. This showed that trastuzumab treatment significantly affects the functional and structural characteristics of the heart. The mechanism of trastuzumab-related cardiotoxicity is not fully understood. This review will summarize the pharmacology and mechanism of trastuzumab-induced cardiotoxicity, investigate its risk factors, and consider the appropriate management for the patients.Discussion: Trastuzumab is a monoclonal antibody, that acts as human epidermal growth factor tyrosine kinase HER2 (Erb B2) antagonist, frequently given for breast cancer patients. Trastuzumab is not only expressed through the excessive HER2 in positive breast cancer but can also disrupt the cardiomyocytes growth and selectively inhibit the structure and function of the heart causing dilated cardiomyopathy. Some studies recommended angiotensin-converting enzyme inhibitor (ACEI), enalapril, to prevent the late cardiotoxicity and angiotensin receptors blocker (ARB) and also beta-blocker (BB), candesartan and bisoprolol, to significantly reduce LV dysfunction event, as the management of trastuzumab-induced cardiotoxicity.Conclusion: Delaying trastuzumab administration after previous anthracycline treatment can prevent or reduce the risk/synergy effect of cardiotoxicity. The temporal withdrawal and reinitiation after LV systolic function stabilization, both spontaneously or using heart failure therapy, partially succeed in preventing cardiotoxicity. And, monitoring the troponin release was found as the first and the most sensitive test to detect cardiotoxicity early signs, with a proven impact on cardiac prognosis, particularly for trastuzumab (after the previous anthracycline).Keywords: Trastuzumab-Induced Cardiotoxicity; Pharmacology Aspect, Mechanism of Cardiotoxicity, Risk Factor and Treatment Strategies.
Literatur Review Trastuzumab Induced Cardiotoxicity (TIC) In Patient With Breast Cancer : Pharmacology Aspect, Mechanism of Cardiotoxicity, Risk Factor and Treatment Strategies Jaya, Nur
Pharmaceutical Journal of Indonesia Vol 5, No 1 (2019)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Breast cancer (BCA) is the most common cancer in women. Since the last 2 decades, early diagnosis and specific molecular targeted neoadjuvant and adjuvant therapy had been reducing breast cancer mortalities. Unfortunately, the improvement of the survival rate is followed by the emergence of cardiotoxicity effect from cancer therapy that had seen in several cases. This showed that trastuzumab treatment significantly affects the functional and structural characteristics of the heart. The mechanism of trastuzumab-related cardiotoxicity is not fully understood. This review will summarize the pharmacology and mechanism of trastuzumab-induced cardiotoxicity, investigate its risk factors, and consider the appropriate management for the patients.Discussion: Trastuzumab is a monoclonal antibody, that acts as human epidermal growth factor tyrosine kinase HER2 (Erb B2) antagonist, frequently given for breast cancer patients. Trastuzumab is not only expressed through the excessive HER2 in positive breast cancer but can also disrupt the cardiomyocytes growth and selectively inhibit the structure and function of the heart causing dilated cardiomyopathy. Some studies recommended angiotensin-converting enzyme inhibitor (ACEI), enalapril, to prevent the late cardiotoxicity and angiotensin receptors blocker (ARB) and also beta-blocker (BB), candesartan and bisoprolol, to significantly reduce LV dysfunction event, as the management of trastuzumab-induced cardiotoxicity.Conclusion: Delaying trastuzumab administration after previous anthracycline treatment can prevent or reduce the risk/synergy effect of cardiotoxicity. The temporal withdrawal and reinitiation after LV systolic function stabilization, both spontaneously or using heart failure therapy, partially succeed in preventing cardiotoxicity. And, monitoring the troponin release was found as the first and the most sensitive test to detect cardiotoxicity early signs, with a proven impact on cardiac prognosis, particularly for trastuzumab (after the previous anthracycline).Keywords: Trastuzumab-Induced Cardiotoxicity; Pharmacology Aspect, Mechanism of Cardiotoxicity, Risk Factor and Treatment Strategies.
Overview of the Use of Oralit and Zinc in Children with Diarrhea at the Community Health Center: Gambaran Penggunaan Oralit dan Zinc Pada Anak Penderita Diare Di Puskesmas Jaya, Nur; Saskia, Ni Nyoman Lisna
Indonesian Journal of Innovation Multidisipliner Research Vol. 1 No. 2 (2023): June
Publisher : Institute of Advanced Knowledge and Science

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69693/ijim.v1i2.156

Abstract

Diarrhea is still one of the main problems can cause illness and death, especially in children. Diarrhea is an infectious disease caused by bacteria, virus or other microorganism which is characterized by abnormal frequency of defecation, 3 or more times in 24 hours with a soft feces consistency, the presence or absence of blood or foam in the feces. Giving oralit and zinc can reduce the incidence of diarrhea in children. The aim of this study was to determine the description of the use oralit and zinc in children suffering from diarrhea at the kawatuna Community Health Center during the peroid October 2022-March 2023. Method of this study is retrospective descriptive using secondary data, namely prescription sheets for pediatric patients with diarrhea who received oralit and zinc therapy. The research results showed that the population of diarrhea cases was 125 and the sample used was 96 cases. The highest use of oralit and zinc for treating casess of diarrhea is in October 2022 and the least in March 2023. The age of children most a affected by diarrhea is 1-6 months (50%) and the age least affected by diarrhea is 12-17 years (7,3%).
Overview of the Use of Oralit and Zinc in Children with Diarrhea at the Community Health Center: Gambaran Penggunaan Oralit dan Zinc Pada Anak Penderita Diare Di Puskesmas Jaya, Nur; Saskia, Ni Nyoman Lisna
Indonesian Journal of Innovation Multidisipliner Research Vol. 1 No. 2 (2023): June
Publisher : Institute of Advanced Knowledge and Science

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69693/ijim.v1i2.156

Abstract

Diarrhea is still one of the main problems can cause illness and death, especially in children. Diarrhea is an infectious disease caused by bacteria, virus or other microorganism which is characterized by abnormal frequency of defecation, 3 or more times in 24 hours with a soft feces consistency, the presence or absence of blood or foam in the feces. Giving oralit and zinc can reduce the incidence of diarrhea in children. The aim of this study was to determine the description of the use oralit and zinc in children suffering from diarrhea at the kawatuna Community Health Center during the peroid October 2022-March 2023. Method of this study is retrospective descriptive using secondary data, namely prescription sheets for pediatric patients with diarrhea who received oralit and zinc therapy. The research results showed that the population of diarrhea cases was 125 and the sample used was 96 cases. The highest use of oralit and zinc for treating casess of diarrhea is in October 2022 and the least in March 2023. The age of children most a affected by diarrhea is 1-6 months (50%) and the age least affected by diarrhea is 12-17 years (7,3%).
Pengaruh Hemodialisa Terhadap Nilai Hemoglobin dan Kreatinin Pada Pasien Penyakit Ginjal Kronik Di Unit Hemodialisa RSUD Undata Jaya, Nur; Tanjung, Revi Maylina; Khoiriyah, Rani; Muharni, Melvi; Setyawan, Teguh; Permatasari, Defia Indah; Rizal B, Muh.; Adam, Meyzaluna Salsabila
Jurnal Altifani Penelitian dan Pengabdian kepada Masyarakat Vol. 5 No. 6 (2025): November 2025 - Jurnal Altifani Penelitian dan Pengabdian kepada Masyarakat
Publisher : Indonesian Scientific Journal

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59395/altifani.v5i6.962

Abstract

Penelitian ini bertujuan untuk mengetahui pengaruh hemodialisa terhadap kadar hemoglobin dan kreatinin pada pasien gagal ginjal kronik di Unit Hemodialisa RSUD Undata. Penelitian ini menggunakan metode kuantitatif dengan desain pre-eksperimental jenis one group pretest-posttest. Sampel sebanyak 88 pasien diambil menggunakan teknik purposive sampling. Data kadar hemoglobin dan kreatinin sebelum dan sesudah hemodialisa dianalisis menggunakan uji Paired Sample T-Test. Hasil penelitian menunjukkan bahwa kadar kreatinin sebelum hemodialisa sebesar 11,464 gr% menurun menjadi 9,211 gr% setelah hemodialisa dengan nilai signifikansi p = 0,00017 (p < 0,05). Sementara itu, kadar hemoglobin meningkat dari 9,440 gr% menjadi 9,939 gr% setelah hemodialisa, dengan nilai p = 0,00053 (p < 0,05). Hasil ini menunjukkan bahwa terdapat perbedaan yang signifikan sebelum dan sesudah hemodialisa. Dapat disimpulkan bahwa hemodialisa memberikan pengaruh yang signifikan terhadap penurunan kadar kreatinin dan peningkatan kadar hemoglobin pada pasien gagal ginjal kronik. Diperlukan pemantauan berkelanjutan terhadap parameter darah lainnya selama terapi hemodialisa untuk mendukung keberhasilan terapi.
Co-Authors Adam, Meyzaluna Salsabila Defia Indah Permatasari Khoiriyah, Rani Melvi Muharmi Rizal B, Muh. Saskia, Ni Nyoman Lisna Setyawan, Teguh Tanjung, Revi Maylina